Information Provided By: 
Fly News Breaks for November 22, 2017
CYTK
Nov 22, 2017 | 07:48 EDT
As previously reported, Cantor Fitzgerald analyst Mara Goldstein downgraded Cytokinetics to Neutral from Overweight after the VITALITY-ALS trial failed and the company announced the discontinuation of the tirasemtiv program. While she sees opportunity for upside as clinical data emerge on omecamtiv and CK-2127107, she argues that the time to meaningful data and proximity to year-end makes a Neutral rating appropriate. Goldstein lowered her price target on Cytokinetics to $10 from $21.
News For CYTK From the Last 2 Days
There are no results for your query CYTK
